Table 2. Amount of different gps giving 50% inhibition of binding of Gleheda (5 ng/50 μl) to asialo PSM (2 ng/50 μl).
The inhibitory activity was estimated from the inhibition curve in Figure 3 and is expressed as the amount of inhibitor giving 50% inhibition. Total volume was 50 μl. Relative potency=quantity of Gal (curve 26) required for 50% inhibition is taken as 1.0/quantity of sample required for 50% inhibition.
| Curve or identification number | Panel in Figure 3 | Gp/glycan | Quantity giving 50% inhibition (ng) | Relative potency |
|---|---|---|---|---|
| 1 | a | Native ASG-Tn (Tn) | 0.2 | 6.5×105 |
| 2 | a | Asialo OSM (Tn) | 0.2 | 6.5×105 |
| 3 | a | ASG-A (sialyl Tn) | 0.4 | 3.3×105 |
| 4 | a | Asialo BSM (Tn) | 0.5 | 2.6×105 |
| 5 | a | Asialo PSM (Tn, Tα, Ah, H) | 0.7 | 1.8×105 |
| 6 | a | OSM (sialyl Tn) | 0.7 | 1.8×105 |
| 7 | a | Asialo HSM (Tn) | 1.2 | 1.1×105 |
| 8 | a | HSM (sialyl Tn, Tn) | 2.4 | 5.4×104 |
| 9 | b | Cyst Mcdon P-1 (I, II, T, Tn) | 3.1 | 4.1×104 |
| 10 | b | Cyst Beach P-1 (I, II, T, Tn) | 3.1 | 4.1×104 |
| 11 | a | PSM (sialyl Tn, Tα, Ah, H) | 7.1 | 1.8×104 |
| 12 | a | BSM (sialyl Tn, sialyl GlcNAcβ1→3Tn) | 8.0 | 1.6×104 |
| 13 | a | Tn-glycophorin (Tn) | 9.9 | 1.3×104 |
| 14 | b | Cyst Tighe P-1 (I/II) | 14.0 | 9.3×103 |
| 15 | b | Cyst MSS first Smith degraded (I, II, T, Tn) | 28.0 | 4.6×103 |
| 16 | b | Cyst 19 (B) | 34.0 | 3.8×103 |
| 17 | b | Cyst Beach phenol insoluble (B) | 70.0 | 1.8×103 |
| 18 | a | Tn-containing glycopeptides | 81.2 | 1.6×103 |
| 19 | b | Sheep hydatid cyst gp (E[P1]) | 120.0 | 1.1×103 |
| 20 | b | Cyst MSS 10% 2× (Ah [A1]) | 125.0 | 1.0×103 |
| 21 | b | Cyst Mcdon (Ah) | 130.0 | 1.0×103 |
| 22 | b | Cyst MSM 10% ppt (Ah [A2]) | 277.0 | 4.7×102 |
| 23 | a, b | GalNAcα1-Ser/Thr (Tn) | 616.0 | 2.1×102 |
| 24 | a | Asialo human glycophorin (Tα) | 800.0* | 1.6×102 |
| 25 | a, b | GalNAc | 3.0×103 | 43.3 |
| 26 | a, b | Gal | 1.3×105 | 1.0 |
| 27 | a | Human glycophorin (sialyl Tα) | >2.8×102 (5.6%)† | − |
| 28 | a | Active antifreeze gp [Tα; molecular mass (1.0–2.1)×104] | >2.8×102 (10.3%) | − |
| 29 | a | Inactive antifreeze gp [Tα; molecular mass (2.6–3.8)×103] | >2.8×102 (10.0%) | − |
| 30 | b | Cyst 9 phenol-insoluble (Ah) | >2.8×102 (26.9%) | − |
| 31 | b | Cyst Tighe phenol-insoluble (H, Leb) | >2.8×102 (2.2%) | − |
| 32 | b | Cyst JS phenol-insoluble (H) | >2.8×102 (14.9%) | − |
| 33 | b | Fetuin (sialyl II, T) | >2.8×102 (14.9%) | − |
| 34 | b | Asialo fetuin (II, T) | >2.8×102 (6.9%) | − |
| 35 | b | Asialo human α1-acid gp (II) | >2.8×102 (12.8%) | − |
| 36 | b | Human α1-acid gp (sialyl II) | >2.8×102 (0.3%) | − |
| 37 | b | Pneumococcus type 14 polysaccharide (II) | >2.8×102 (1.5%) | − |
| 38 | b | Mannan | >2.8×102 (10.8%) | − |
* Extrapolation value.
† The inhibitory potency of inactive gps are expressed as the maximum amount of gps tested that yield inhibition (in parentheses) below 50%.